Showing 7821-7830 of 10166 results for "".
- Incyte Opens Applications for HS-Focused Ingenuity Awardshttps://practicaldermatology.com/news/incyte-opens-applications-for-hs-focused-ingenuity-awards/2484308/Incyte has announced the launch of the Incyte Ingenuity Awards (IIA) in Hidradenitis Suppurativa (HS), a new initiative developed in collaboration with patients, advocates, and clinicians to address challenges faced by HS patients, according to a press release from
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://practicaldermatology.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://practicaldermatology.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Upadacitinib Demonstrates Rapid Improvement in AD Patients With Prurigo Noduleshttps://practicaldermatology.com/news/upadacitinib-demonstrates-rapid-improvement-in-ad-patients-with-prurigo-nodules/2484113/A new interim analysis from the ADMIRE study, presented at the 2025 Fall Clinical Dermatology Conference, reported that upadacitinib yields rapid and sustained improvements in patients with moderate-to-severe atopic dermatitis (AD) complicated by prurigo nodules, o
- New Review Highlights TWEAK/Fn14 Pathway's Potentialhttps://practicaldermatology.com/news/new-review-highlights-tweakfn14-pathways-potential/2484097/A new review published in International Immunopharmacology explores the expanding role of the TWEAK/Fn14 signaling pathway in both skin disease pathogenesis and stem cell regulation, proposing its potential as a dual-purpose
- Dr. James Del Rosso Presents 'Medicine Chest' at Fall Clinicalhttps://practicaldermatology.com/news/dr-james-del-rossos-presents-medicine-chest-at-fall-clinical/2484096/A curated overview of skincare fundamentals, treatment pearls, and emerging data across acne, rosacea, hyperpigmentation, hidradenitis suppurativa (HS), and more was on display as James Q. Del Rosso, DO, presented “What’s New in the Medicine Chest” at the 2025 Fall Clinical Dermatology Conference
- Dr. Peter Lio Named Fall Clinical Educator of the Yearhttps://practicaldermatology.com/news/dr-peter-lio-named-fall-clinical-educator-of-the-year/2484092/Peter Lio, MD, was presented with the Educator of the Year Award at the 2025 Fall Clinical Dermatology Conference. Dr. Lio is founding director of the Chicago Integrative Eczema Center and a member of Practical Dermatology’s Editorial Board. Dr. Lio spoke at the Fall Clinical Meetin
- Long-Term Baricitinib Data Reinforce Potential in Adolescents With AAhttps://practicaldermatology.com/news/long-term-baricitinib-data-reinforce-potential-in-adolescents-with-aa/2484088/More than half of adolescents treated for alopecia areata (AA) with baricitinib 4mg achieved successful scalp hair response by Week 52, with a response rate reaching 71% among those with baseline Severity of Alopecia Tool (SALT) score of 50-94, according to new data presented at the 2025 Fall Cli
- Arcutis Presents New ZORYVE Data in AD at Fall Clinical 2025https://practicaldermatology.com/news/arcutis-presents-new-zoryve-data-in-ad-at-fall-clinical-2025/2484062/Updates and new data sets from the INTEGUMENT trial program, including new quality-of-life and efficacy data for ZORYVE® (roflumilast) cream in pediatric and adult patients with atopic dermatitis (AD), were featured at the 2025 Fall Clinical Dermatology Conference